Wall Street waffled before finishing lower today as oil prices also see-sawed and traders weighed lacklustre earnings from Xerox Corp against a surge in housing prices.

ELAN and Biogen’s new multiple sclerosis drug, Tysabri, will be priced 30% dearer than expectations lifting the prospects of Elan returning to profitability in 2006.